

# Dimitrios C Ziogas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8435682/publications.pdf>

Version: 2024-02-01

87  
papers

2,123  
citations

279798

23  
h-index

276875

41  
g-index

87  
all docs

87  
docs citations

87  
times ranked

3408  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy for pancreatic cancer: A 2020 update. <i>Cancer Treatment Reviews</i> , 2020, 86, 102016.	7.7	276
2	Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2012, 7, e48135.	2.5	163
3	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017, 1, 449-454.	5.2	89
4	Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. , 2019, 7, 239.		81
5	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. <i>PLoS ONE</i> , 2015, 10, e0116189.	2.5	77
6	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016, 91, 499-502.	4.1	73
7	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017, 102, 593-599.	3.5	72
8	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	1.4	54
9	Meta-analysis: the effects of placebo treatment on gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 29-42.	3.7	52
10	Oxidative stress and inflammatory markers in the exhaled breath condensate of children with OSA. <i>Sleep and Breathing</i> , 2012, 16, 703-708.	1.7	48
11	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.	4.1	48
12	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.	1.4	44
13	Analysis of the Quality of Reporting of Randomized Controlled Trials in Acute and Chronic Myeloid Leukemia, and Myelodysplastic Syndromes as Governed by the CONSORT Statement. <i>Annals of Epidemiology</i> , 2009, 19, 494-500.	1.9	42
14	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	7.2	40
15	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 46.	6.2	39
16	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	5.2	37
17	MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. <i>Pharmacogenomics</i> , 2009, 10, 1285-1294.	1.3	36
18	Intestinal Upregulation of Melanin-Concentrating Hormone in TNBS-Induced Enterocolitis in Adult Zebrafish. <i>PLoS ONE</i> , 2013, 8, e83194.	2.5	33

#	ARTICLE	IF	CITATIONS
19	Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. <i>Blood Cancer Journal</i> , 2017, 7, e571-e571.	6.2	33
20	Serum correlates of the placebo effect in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2010, 22, 285-e81.	3.0	32
21	Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. <i>Blood Cancer Journal</i> , 2017, 7, e570-e570.	6.2	31
22	Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. <i>BMC Cancer</i> , 2018, 18, 1247.	2.6	29
23	Prognostic factors for multiple myeloma in the era of novel therapies. <i>Expert Review of Hematology</i> , 2018, 11, 863-879.	2.2	28
24	A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly. <i>Clinical Therapeutics</i> , 2011, 33, 254-279.	2.5	27
25	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103663.	4.4	27
26	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
27	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017, 58, 1832-1839.	1.3	24
28	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	3.0	24
29	An overview of the role of carfilzomib in the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1883-1897.	1.8	23
30	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
31	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.4	23
32	Treating ALK-positive non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 141-141.	1.7	23
33	Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. <i>Vaccines</i> , 2021, 9, 1111.	4.4	22
34	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	4.1	21
35	Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: A synthesis of genetic association studies. <i>Cancer Epidemiology</i> , 2012, 36, 169-176.	1.9	20
36	Combination of conventional culture, vial culture, and broad-range PCR of sonication fluid for the diagnosis of prosthetic joint infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 13-18.	1.8	20

#	ARTICLE	IF	CITATIONS
37	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	2.7	20
38	Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. <i>Blood Cancer Journal</i> , 2016, 6, e428-e428.	6.2	19
39	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 48-55.	1.6	18
40	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	6.7	18
41	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.2	17
42	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	1.8	17
43	An overview of antibody-drug conjugates in oncological practice. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096299.	3.2	15
44	You deserve what you eat: lessons learned from the study of the melanin-concentrating hormone (MCH)-deficient mice. <i>Gut</i> , 2010, 59, 1625-1634.	12.1	14
45	Field Synopsis and Synthesis of Genetic Association Studies in Osteoarthritis: The CUMAGAS-OSTEO Information System. <i>American Journal of Epidemiology</i> , 2010, 171, 851-858.	3.4	14
46	FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis. <i>Biomarkers</i> , 2012, 17, 532-538.	1.9	13
47	The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 113.	1.9	13
48	Inflammation-induced functional connectivity of melanin-concentrating hormone and IL-10. <i>Peptides</i> , 2014, 55, 58-64.	2.4	13
49	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <i>Annals of Translational Medicine</i> , 2018, 6, 143-143.	1.7	13
50	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.	4.1	11
51	Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G876-G884.	3.4	9
52	Increased Susceptibility of Melanin-Concentrating Hormone-Deficient Mice to Infection with <i>Salmonella enterica</i> Serovar Typhimurium. <i>Infection and Immunity</i> , 2013, 81, 166-172.	2.2	9
53	Asymptomatic Bacteriuria in Women With Autoimmune Rheumatic Disease: Prevalence, Risk Factors, and Clinical Significance. <i>Clinical Infectious Diseases</i> , 2015, 60, 868-874.	5.8	9
54	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	1.8	9

#	ARTICLE	IF	CITATIONS
55	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	1.3	9
56	The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110473.	3.2	9
57	Bone mineral density and genetic markers involved in three connected pathways (focal adhesion, actin) Tj ETQq1 1 0.784314 rgBT /O 698-708.	1.9	8
58	Reduced Intestinal Tumorigenesis in APCmin Mice Lacking Melanin-Concentrating Hormone. <i>PLoS ONE</i> , 2012, 7, e41914.	2.5	8
59	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. <i>BMC Medical Genetics</i> , 2019, 20, 23.	2.1	8
60	Prognosis and Management of <i>BRAF</i> V600E-Mutated Pregnancy-Associated Melanoma. <i>Oncologist</i> , 2020, 25, e1209-e1220.	3.7	7
61	Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. <i>BMC Gastroenterology</i> , 2021, 21, 227.	2.0	7
62	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 53-62.	2.4	6
63	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF</i> <sup>V600</sup> -positive melanoma: Interim analysis of the ImmunoCobiVern study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9548-9548.	1.6	6
64	Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature. <i>Journal of Immunotherapy</i> , 2020, 43, 224-229.	2.4	5
65	A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness. <i>Vaccine</i> , 2021, 39, 1593-1597.	3.8	5
66	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600E-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9540-9540.	1.6	5
67	When to recommend a second autograft in patients with relapsed myeloma?. <i>Leukemia and Lymphoma</i> , 2017, 58, 781-787.	1.3	4
68	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2018, 59, 983-987.	1.3	4
69	Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci <i>et al</i> ., 2021, 9, e002391.		3
70	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. <i>Blood</i> , 2018, 132, 1966-1966.	1.4	3
71	Carfilzomib for treating myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 989-999.	0.8	2
72	Gefitinib: an "orphan" drug for non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 899-906.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. Bone Marrow Transplantation, 2017, 52, 1537-1542.	2.4	2
74	Circulating autoantibodies to endogenous erythropoietin are associated with chronic hepatitis C virus infection-related anemia. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 289-295.	1.3	2
75	Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review. Frontiers in Oncology, 2021, 11, 727010.	2.8	2
76	POEMS Syndrome. Hematologic Malignancies, 2018, , 177-189.	0.2	1
77	Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096236.	3.2	1
78	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. Blood, 2018, 132, 1968-1968.	1.4	1
79	Omitting chemotherapy in more patients with early breast cancer in the post-TAILORx era.. Journal of Clinical Oncology, 2020, 38, e12534-e12534.	1.6	1
80	Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers. Cancers, 2022, 14, 2873.	3.7	1
81	Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e62-e63.	0.4	0
82	Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e115-e116.	0.4	0
83	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S331-S332.	0.4	0
84	Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. Expert Review of Precision Medicine and Drug Development, 2021, 6, 349-360.	0.7	0
85	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. Blood, 2018, 132, 3247-3247.	1.4	0
86	Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd. Blood, 2018, 132, 3246-3246.	1.4	0
87	The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211047349.	3.2	0